Results 41 to 50 of about 4,766 (189)

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

AIDS Research and Therapy, 2017
Background As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and ...
Marianne Harris, Bruce Ganase, Birgit Watson, P. Richard Harrigan, Julio S. G. Montaner, Mark W. Hull   +5 more
doaj   +1 more source

Drug-Induced Urinary Stone of Atazanavir Incidentally Found in an Asymptomatic Patient: A Case Report

Case Reports in Urology, 2023
A HIV-infected female treated with a combination of emtricitabine/elvitegravir/tenofovir since 2017 presented an acute renal failure during her hospitalization for a SARS-CoV2 pneumonia.
Maëlle Plawecki, Marie Bistoquet, Pierre-Edouard Grillet, Nicolas Abdo, Jean-Sébastien Souweine, Jean-Paul Cristol   +5 more
doaj   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

, 2016
Objectives: To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation. Methods: Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day ...
Owen, A, Else, L, Boffito, M, Amara, A, Elliot, E, Khoo, S, Moyle, G, Back, D, Jackson, A   +8 more
core   +1 more source

New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis

Metabolism Open, 2023
Objectives: The development of diabetes mellitus (DM) in patients taking integrase strand transfer inhibitors (INSTIs) has raised concerns. It's critical because, in most guidelines, INSTIs are the preferred third agent at first-line regimens. This study
Violet Dismas Kajogoo, Wondwossen Amogne, Girmay Medhin   +2 more
doaj   +1 more source

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response

Scientific Reports, 2023
In this study, we investigated the potential of using curcumin (CUR) as an adjuvant to enhance the delivery of antiretroviral drug elvitegravir (EVG) across the BBB, and alleviate oxidative stress and inflammatory response, which are the major hallmark ...
Sandip Godse, Lina Zhou, Namita Sinha, Sunitha Kodidela, Asit Kumar, Udai P. Singh, Santosh Kumar   +6 more
doaj   +1 more source

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, Volume 27, Issue 5, Page 761-770, May 2026.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

, 2019
International audienceIntegrase inhibitors are increasingly used in combined antiretroviral therapy (ART) because of their high efficacy in inhibiting HIV replication and favourable tolerance profile.
Metsu, David, Delobel, Pierre, Martin-Blondel, Guillaume, Izopet, Jacques, Raymond, Stéphanie, Gandia, Peggy, Guerveno, Claire   +6 more
core   +1 more source

DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF ELVITEGRAVIR (EVG) IN BULK AND PHARMACEUTICAL FORMULATIONS [PDF]

, 2020
A simple, rapid, precise and economical spectrophotometric method has been developed for quantitative analysis of Elvitegravir (EVG) in manufactured tablet formulation. The stock solution and subsequent dilution of Elvitegravir was done in methanol.
Kiran B Aher, S R Chaudhari, Swati S Pardhi, Girija B Bhavar   +3 more
core  

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source